Treatment of congestive heart failure - a neuroendocrine disorder

被引：6

作者：

Martin, MWS ^{[1
]}

机构：

[1] Vet Cardioresp Ctr, Kenilworth CV8 1JL, Warwick, England

来源：

JOURNAL OF SMALL ANIMAL PRACTICE | 2003年 / 44卷 / 04期

关键词：

D O I：

10.1111/j.1748-5827.2003.tb00137.x

中图分类号：

S85 [动物医学（兽医学）];

学科分类号：

0906 ;

摘要：

The understanding of heart failure is no longer based on a supply and demand model of pump failure. Rather, heart failure is seen as a complex pathophysiological process with activation of various neuroendocrine systems. The goals of treatment have changed towards modifying these counterproductive neuroendocrine systems and slowing myocardial maladaptation. Angiotensin converting enzyme inhibitors are the only licensed drugs in veterinary practice that have a direct effect on neurohormones in heart failure. The range of drug options in human medicine is greater and some of these drugs are also increasingly being used in veterinary cardiology practice. This review describes the neuroendocrine systems involved in heart failure and discusses the range of drugs available in human and veterinary medicine. In doing so, it concentrates on the evidence available from good quality randomised trials in both the veterinary field and, where relevant, the human medical field.

引用

页码：154 / 160

页数：7

共 43 条

[31]

PARKERWARD R, 2001, POSTGRAD MED, V109, P36

[32]

Perry G, 1997, NEW ENGL J MED, V336, P525

[33] Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II [J].

Pitt, B ;

Poole-Wilson, PA ;

Segal, R ;

Martinez, FA ;

Dickstein, K ;

Camm, AJ ;

Konstam, MA ;

Riegger, G ;

Klinger, GH ;

Neaton, J ;

Sharma, D ;

Thiyagarajan, B .

LANCET, 2000, 355 (9215) :1582-1587

[34] The effect of spironolactone on morbidity and mortality in patients with severe heart failure [J].

Pitt, B ;

Zannad, F ;

Remme, WJ ;

Cody, R ;

Castaigne, A ;

Perez, A ;

Palensky, J ;

Wittes, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (10) :709-717

[35] The lipophilic properties of angiotensin I-converting enzyme inhibitors do not influence their diffusion through cultured endothelium [J].

Raasch, W ;

Dendorfer, A ;

Ball, B ;

Dominiak, P .

JAPANESE JOURNAL OF PHARMACOLOGY, 1999, 81 (04) :346-352

[36] Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial [J].

Rouleau, JL ;

Pfeffer, MA ;

Stewart, DJ ;

Isaac, D ;

Sestier, F ;

Kerut, EK ;

Porter, CB ;

Proulx, G ;

Qian, CL ;

Block, AJ .

LANCET, 2000, 356 (9230) :615-620

[37] Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure [J].

Silver, MA ;

Horton, DP ;

Ghali, JK ;

Elkayam, U .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (05) :798-803

[38] DIGOXIN IN HEART-FAILURE [J].

SMITH, TW .

NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (01) :51-53

[39] Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure [J].

Sütsch, G ;

Kiowski, W ;

Yan, XW ;

Hunziker, P ;

Christen, S ;

Strobel, W ;

Kim, JH ;

Rickenbacher, P ;

Bertel, O .

CIRCULATION, 1998, 98 (21) :2262-2268

[40]

SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429

← 1 2 3 4 5 →